KIF20B

Across TCGA pan-cancer cohorts, KIF20B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KIF20B data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher KIF20B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated KIF20B expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where KIF20B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.944	0.292	.001	21	view →
LUAD	OS	Median	All	0.864	1.000	.015	10	view →
PDAC	DFS	Quartile	II,III,IV	0.687	0.319	.010	8	view →
HNSC	OS	Quartile	IV	1.000	0.474	.014	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

KIF20B–LSCC (DFS)

Open the LSCC breakdown →